Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 ((111)In)/Yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin(®)) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels

SIMPLE SUMMARY: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin’s lymphoma using the theranostic pair of (111)In and (90)Y anti-CD20 ibritumomab tiuxetan (Zevalin(®)) at myeloablat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahl, Richard L., Frey, Eric C., Jacene, Heather A., Kahl, Brad S., Piantadosi, Steven, Bianco, Jesus A., Hammes, Richard J., Jung, Miah, Kasecamp, Wayne, He, Bin, Sgouros, George, Flinn, Ian W., Swinnen, Lode J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201215/
https://www.ncbi.nlm.nih.gov/pubmed/34204102
http://dx.doi.org/10.3390/cancers13112828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201215/
https://www.ncbi.nlm.nih.gov/pubmed/34204102
http://dx.doi.org/10.3390/cancers13112828

Ejemplares similares